Should patient-reported outcomes be mandatory for toxicity reporting in cancer clinical trials?

[1]  B. Zee,et al.  Assessing the reliability of two toxicity scales: implications for interpreting toxicity data. , 1993, Journal of the National Cancer Institute.

[2]  W. Kuo,et al.  Quality of life as a survival predictor for esophageal squamous cell carcinoma treated with radiotherapy. , 2004, International journal of radiation oncology, biology, physics.

[3]  A. Garden,et al.  TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. , 2007, The Lancet. Oncology.

[4]  D. Roychowdhury,et al.  Health-related quality-of-life parameters as independent prognostic factors in advanced or metastatic bladder cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  M. Piccart,et al.  Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. , 2004, European journal of cancer.

[6]  D. Bruner.  Outcomes research in cancer symptom management trials: the Radiation Therapy Oncology Group (RTOG) conceptual model. , 2007, Journal of the National Cancer Institute. Monographs.

[7]  J. Sloan,et al.  The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer. , 2002, Journal of the National Cancer Institute.

[8]  D. Cella,et al.  RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. , 1995, International journal of radiation oncology, biology, physics.

[9]  M. Parliament,et al.  Is cancer treatment toxicity accurately reported? , 1985, International journal of radiation oncology, biology, physics.

[10]  R. Komaki,et al.  Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Kai Lin,et al.  Application of Information Technology: Evaluation of an Online Platform for Cancer Patient Self-reporting of Chemotherapy Toxicities , 2007, J. Am. Medical Informatics Assoc..

[12]  N. Aaronson,et al.  The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Y. Ohashi,et al.  [Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0]. , 2004, Gan to kagaku ryoho. Cancer & chemotherapy.

[14]  M. Jensen,et al.  The validity and reliability of pain measures in adults with cancer. , 2003, The journal of pain : official journal of the American Pain Society.

[15]  B. Monk,et al.  Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  David Artz,et al.  Long-term toxicity monitoring via electronic patient-reported outcomes in patients receiving chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.